Search Results

You are looking at 1 - 10 of 34 items for :

  • dopamine agonists x
Clear All
Open access

Sarah Byberg, Jesper Futtrup, Mikkel Andreassen and Jesper Krogh

levels correlated with insulin resistance in patients with polycystic ovary syndrome ( 21 ). Dopamine is the natural negative regulator of prolactin release from the anterior pituitary gland, and dopamine D2 receptor agonists are the first line of

Open access

Anastasia P Athanasoulia-Kaspar, Kathrin H Popp and Gunter Karl Stalla

Introduction Case report To emphasize the possible role of dopamine agonists in the development of impulse control disorders that could be potentially devastating for the patient’s life, we report a case of a giant-prolactinoma in a young

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide therapy (PRRT). We analyzed PRRT effectiveness, safety and long-term outcome in three patients with aggressive PT, also reviewing the current literature. Patient #1 (F, giant prolactinoma) received five cycles (total dose 37 GBq) of 111In-DTPA-octreotide over 23 months, after unsuccessful surgery and long-term dopamine-agonist treatment. Patient #2 (M, giant prolactinoma) underwent two cycles (12.6 GBq) of 177Lu-DOTATOC after multiple surgeries, radiosurgery and TMZ. In patient #3 (F, non-functioning PT), five cycles (29.8 GBq) of 177Lu-DOTATOC followed five surgeries, radiotherapy and TMZ. Eleven more cases of PRRT-treated aggressive PT emerged from literature. Patient #1 showed tumor shrinkage and visual/neurological amelioration over 8-year follow-up, while the other PTs continued to grow causing blindness and neuro-cognitive disorders (patient #2) or monolateral amaurosis (patient #3). No adverse effects were reported. Including the patients from literature, 4/13 presented tumor shrinkage and clinical/biochemical improvement after PRRT. Response did not correlate with patients’ gender or age, neither with used radionuclide/peptide, but PRRT failure was significantly associated with previous TMZ treatment. Overall, adverse effects occurred only in two patients. PRRT was successful in 1/3 of patients with aggressive PT, and in 4/5 of those not previously treated with TMZ, representing a safe option after unsuccessful multimodal treatment. However, at present, considering the few data, PRRT should be considered only in an experimental setting.

Open access

L Bahler, H J Verberne, E Brakema, R Tepaske, J Booij, J B Hoekstra and F Holleman

. Recently, a quick release variant of bromocriptine has emerged as a new glucose-lowering treatment in obese patients with type 2 diabetes mellitus. Bromocriptine is a centrally acting dopamine D 2 -receptor agonist, but it also weakly stimulates the

Open access

Ali Abbara, Sophie Clarke, Pei Chia Eng, James Milburn, Devavrata Joshi, Alexander N Comninos, Rozana Ramli, Amrish Mehta, Brynmor Jones, Florian Wernig, Ramesh Nair, Nigel Mendoza, Amir H Sam, Emma Hatfield, Karim Meeran, Waljit S Dhillo and Niamh M Martin

4/52  Antiplatelet or anticoagulant 3/52  Dopamine agonists 2/52  Radiotherapy 2/52  None 24/52 Type of secretion of adenoma defined clinically or biochemically  NF or GT 47/52  PRL 5

Open access

Enrique Soto-Pedre, Paul J Newey, John S Bevan and Graham P Leese

hyperprolactinaemia may be associated with heart valve disease (including that related to the use of dopamine agonist therapy), cardiovascular risk factors or cardiovascular mortality ( 4 , 5 , 6 , 7 ). Results from epidemiologic studies that have examined the

Open access

Stavroula Stavrou, Michael Gratz, Eileen Tremmel, Christina Kuhn, Simone Hofmann, Helene Heidegger, Mina Peryanova, Kerstin Hermelink, Stefan Hutter, Bettina Toth, Doris Mayr, Sven Mahner, Udo Jeschke and Aurelia Vattai

of neuroscience whereby it could be shown that TAAR1 is able to modulate the serotonergic and dopaminergic system in the brain ( 15 ). As TAAR1 is a negative regulator of dopamine transmission, TAAR1 and its agonists as well as antagonists represent a

Open access

Konstantin Yakimchuk, Chandrashekar Bangalore Revanna, Dan Huang, Jose Inzunza and Sam Okret

estrogen synthesis by administrating aromatase inhibitors enhanced lymphoma progression in both female and male mice ( 30 ). Importantly, we have also shown that treatment of mice with selective ESR2 agonists inhibits growth of both grafted murine T cell

Open access

Lijin Ji, Na Yi, Qi Zhang, Shuo Zhang, Xiaoxia Liu, Hongli Shi and Bin Lu

effects. Tumor mass effects can cause visual field defects, decreased vision, headaches and can even be life threatening. Drug therapy is recommended for prolactinoma, and the dopamine receptor agonists (DAs) bromocriptine and cabergoline are commonly

Open access

Gavin P Vinson and Caroline H Brennan

replacement 198 Reduced Fos response to dopamine agonist, enhanced dopamine response to cocaine 199 Decreased cocaine-induced locomotor sensitisation 200 With corticosterone hemi-succinate replacement; up to 3 mg/kg implant Restoration of cocaine